Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "ulcerative-colitis"

57 News Found

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab
Clinical Trials | August 20, 2022

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets


Athos announces research collaboration to advance precision medicine in inflammatory bowel disease
News | July 13, 2022

Athos announces research collaboration to advance precision medicine in inflammatory bowel disease

Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples


CHMP recommends European Commission approval of Rinvoq
Drug Approval | May 23, 2022

CHMP recommends European Commission approval of Rinvoq

Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients


Janssen’s icare4u to assist people living with skin, joint and digestive disorders
Healthcare | May 19, 2022

Janssen’s icare4u to assist people living with skin, joint and digestive disorders

The icare4u program features a dedicated website, with comprehensive information about the diseases, videos with medical experts, and a social media community for patients and caregivers on Facebook and YouTube


Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn
News | December 14, 2021

Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn

The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases


FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Drug Approval | October 20, 2021

FDA approves Cyltezo, the first interchangeable biosimilar to Humira

Second interchangeable biosimilar product approved by agency


Zydus Cadila receives final approval for Mesalamine extended-release capsules
Drug Approval | August 16, 2021

Zydus Cadila receives final approval for Mesalamine extended-release capsules

The group has a total of 320 ANDA approvals